Pro-Resolving Mediators in Acute Inflammation in Humans
Who is this study for? Healthy adult volunteers age 18 to 64
What treatments are being studied? Cantharone+Lovaza
Status: Completed
Location: See location...
Intervention Type: Other, Drug
Study Type: Interventional
Study Phase: Early Phase 1
SUMMARY
The investigators are undertaking a clinical blister model with or without dietary supplementation with omega-3 fatty acids (i.e., Lovaza) to determine the role of specialized pro-resolving mediators - endogenous lipids converted from omega-3 fatty acid precursors including those in Lovaza - on inflammation parameters and their resolution.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 64
Healthy Volunteers: t
View:
• Healthy adults
• Ages 18-64
Locations
United States
Massachusetts
Brigham and Women's Hospital
Boston
Time Frame
Start Date: 2018-07-02
Completion Date: 2022-02-22
Participants
Target number of participants: 19
Treatments
Active_comparator: Without Supplementation
No planned dietary supplementation
Experimental: With Supplementation
The subject will take 4 capsules (1gram each) of Lovaza daily at 8pm, starting the evening before blister induction and continuing until the second blister fluid has been removed.
Authors
Charles N Serhan, Katherine H Walker, Bruce D Levy
Related Therapeutic Areas
Sponsors
Leads: Brigham and Women's Hospital
Collaborators: National Institute of General Medical Sciences (NIGMS)